|Bid||63.12 x 1400|
|Ask||0.00 x 900|
|Day's Range||69.16 - 70.98|
|52 Week Range||47.98 - 84.37|
|Beta (3Y Monthly)||2.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||81.46|
NEW YORK, NY / ACCESSWIRE / April 25, 2019 / Seattle Genetics, Inc. (NASDAQ: SGEN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 25, 2019 at 4:30 PM ...
"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]
Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a really great company, you can more than double your money. To wit, the Seattle Genetics, Inc. (NASDAQ:SGEN...
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
The cancer treatment market is a massive one, and the companies that produce these treatments often make strong investment opportunities. With so much financial opportunity in the space and several areas with medical need, oncology stocks tend to be met with heavy investor interest. Warning! GuruFocus has detected 6 Warning Signs with SGEN.
Seattle Genetics Inc NASDAQ/NGS:SGENView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderate for SGEN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $1.17 billion over the last one-month into ETFs that hold SGEN are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Seattle Genetics, Inc. announced today that it will report its first quarter 2019 financial results on Thursday, April 25, 2019 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
Seattle Genetics (SGEN) and partner Genmab end enrollment in the phase II study on tisotumab vedotin for treating patients with advanced/metastatic cervical cancer.
Seattle Genetics (SGEN) and partner Astellas present positive top-line data from the first cohort of a phase II study on enfortumab vedotin for treating patients with advanced/metastatic urothelial cancer.
-Phase 2 innovaTV 204 Trial Designed to Support Potential Accelerated Approval Pathway in U.S.-
Seattle Genetics stock initially approached a breakout Thursday after its bladder cancer treatment outperformed expectations in a test. But shares fell into the red at the closing bell.
Seattle Genetics, Inc. will host a conference call and webcast discussion regarding the positive topline results from its pivotal clinical trial of enfortumab vedotin in locally advanced or metastatic urothelial cancer, which were announced in a press release earlier today.
BOTHELL, Wash. and TOKYO, March 28, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive topline results from the first cohort of patients in a pivotal phase 2 single-arm clinical trial known as EV-201. The cohort is evaluating enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received previous treatment with both platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor. Enfortumab vedotin is an investigational antibody-drug conjugate (ADC) that targets Nectin-4, a therapeutic target that is highly expressed in multiple solid tumors including urothelial cancers.
Seattle Genetics, Inc. today announced data highlights from six presentations showcasing technology advances in the company’s antibody-drug conjugate platform and an immuno-oncology program at the American Association for Cancer Research Annual Meeting 2019 being held March 29-April 3, 2019 in Atlanta.
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Flagship ImmunoGen (IMGN) ovarian cancer drug candidate Mirvetuximab Soravtansine just failed to meet its primary endpoint in Phase III studies. The failed candidate is an antibody-drug conjugate (ADC), a drug model that uses an antibody as a homing device to lock on to cancer cells and deliver a targeted drug payload. The entire ADC approach to cancer treatment could arguably be called into question here.
These stocks are heavily owned by high-turnover hedge funds, and thus are likely to face severe selling pressure once these funds turn bearish.
Seattle Genetics, Inc.'s (NASDAQ:SGEN): Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. On 31 December 2018, theRead More...
Seattle Genetics, Inc. announced today that management will present at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 10:40 a.m.
Commercial real estate investors are seeking out opportunities in places like Bothell where prices are lower relative to much of the rest of the Eastside.